« Resolving the Class Action Crisis: Mass Tort Litigation as Network | Main | Coke Trying to Use Expected Guilty Plea by Lerach to Deny Class Status Based on Inadequate Representation »
October 22, 2007
Follow-up on Prempro Trial
An Associated Press story in today's Reno Gazette Journal follows up on the Nevada Prempro plaintiffs' verdict. The main point of the article -- No alarm on Wall Street over Wyeth case -- is that the financial markets are not particularly concerned about the litigation over the Prempro and Premarin hormone replacement therapy (HRT) drugs, and are treating the $134 million verdict ($35 million compensatory damages and $99 million punitive damages) more as an aberration than an omen. As one financial analyst put it, as quoted in the article, "Unlike Wyeth's diet drug litigation, the Premarin/Prempro is widely viewed as more of a headline risk than a long-term financial risk." Of course, after fen-phen, almost any Wyeth litigation risk would appear small by comparison.
HME
October 22, 2007 in Prempro | Permalink
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/t/trackback/89778/22656950
Listed below are links to weblogs that reference Follow-up on Prempro Trial:
» "No alarm on Wall Street over Wyeth case" from PointOfLaw Forum
Per the AP (via Erichson), markets are shrugging off the $134 million Nevada judgment (see Oct. 11) against the maker of the hormone-replacement drugs Prempro and Premarin. Earlier coverage of Wyeth victories is here, here and here. One stock analyst,... [Read More]
Tracked on Oct 29, 2007 12:24:19 AM
